注册
CN
首页 > 产品中心 > 抗体 > 双特异性抗体

Anti-Human DLL4 & VEGF Bispecific Reference Antibody (Dilpacimab, RUO) (HV571046)

价格:
规格：
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
数量：
联系我们
一键复制产品信息

  • 概述

  • 图片

  • 参考文献

  • 产品说明书

概述
货号HV571046
品牌abinScience
描述
Dilpacimab (HV571046) is a research-grade recombinant antibody targeting Delta-like protein 4. Produced in mammalian cells with native-like glycosylation.
Highlights
  • ●Research Grade — For PK/PD studies, assay development, and ADA research.
  • ●Native Glycosylation — Mammalian expression ensures native-like patterns.
种属反应性Human
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
同种型IgG1-kappa
表达系统Mammalian cells
靶标Delta-like protein 4, Drosophila Delta homolog 4, Delta4, DLL4, Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A
内毒素水平< 10 EU/mg
纯度>95% purity as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
Accession号Q9NR61 & P15692
状态Liquid
保存溶液 0.01M PBS pH 7.4

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
稳定性和存储Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
别名Bispecific, ABT-165, PR-1283233, 1791420-09-1
背景Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways. Here, we present safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data from a phase I study (trial registration ID: NCT01946074) of dilpacimab in patients with advanced solid tumors. Eligible patients (≥18 years) received dilpacimab intravenously on days 1 and 15 in 28-day cycles at escalating dose levels (range, 1.25–7.5 mg/kg) until progressive disease or unacceptable toxicity.
NoteFor research use only. Not suitable for clinical or therapeutic use.
Isotype ControlHuman IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)
图片

  • SEC-HPLC

    SEC-HPLC detection for Research Grade Dilpacimab.

  • Bioactivity

    Detects VEGFA in indirect ELISAs.

  • SDS-PAGE

    SDS-PAGE for Research Grade Dilpacimab

参考文献
产品说明书
公式
质量 (g) = 浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)
填写 质量、浓度、体积中的任意 2 项 + 分子量，自动计算未知值。
质量
=
浓度
×
体积
分子量 *
g/mol
公式
C₁ × V₁ = C₂ × V₂
填写 4 项中的任意 3 项，自动计算未知值。
母液
C₁ (起始浓度)
×
V₁ (起始体积)
=
工作液
C₂ (终浓度)
×
V₂ (终体积)

相关产品推荐

获取报价

Anti-Human DLL4 & VEGF Bispecific Reference Antibody (Dilpacimab, RUO)

  • 7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言

  • 武汉东湖新技术开发区神墩四路666号研发楼B区3层东

  • 24小时产品查询

    24小时产品查询

  • 24小时产品查询

    扫一扫关注我们

  • 24小时产品查询

    专属渠道经理

Copyright © 2026 武汉艾必赛生物科技有限公司版权所有 所有产品仅可用于工业或者科研等非医疗目的。
鄂ICP备2023002448号-2